About Vantia Therapeutics
Vantia Therapeutics is a drug development company. Founded on Ferring Research's 21 year experience in small molecule discovery & early development, Vantia was formed in late 2007 and acquired a series of drug assets and people from Ferring in March 2008. The Company is based on Southampton University's Science Park at Chilworth in the UK. Vantia's lead assets are VT483, a vasopressin agonist in Phase II clinical trials for the treatment of nocturia and VT913, a vasopressin antagonist for the treatment of dysmennhorrea, also in Phase II studies.
Missing: Vantia Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Vantia Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Vantia Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Vantia Therapeutics is included in 1 Expert Collection, including Biopharma Tech.
Vantia Therapeutics Patents
Vantia Therapeutics has filed 1 patent.
Glycine receptor antagonists, Glycine receptor agonists, Amines, Piperidines, Orthorhombic minerals
Glycine receptor antagonists, Glycine receptor agonists, Amines, Piperidines, Orthorhombic minerals
Latest Vantia Therapeutics News
Sep 14, 2021
Nocturnal Polyuria Treatment Market Industry Analysis And Growth By Top Companies 2030 Nocturnal Polyuria Treatment market players – Allergan, Inc., Ferring Holding SA, Teva Pharmaceutical Industries Ltd., Urigen Pharmaceuticals, Vantia Therapeutics, Astellas Pharma Inc. And Urigen Pharmaceutical, among others represent the global Nocturnal Polyuria Treatment market. The market study depicts an extensive analysis of all the players running in the Nocturnal Polyuria Treatment market report based on distribution channels, local network, innovative launches, industrial penetration, production methods, and revenue generation. Further, the market strategies and mergers & acquisitions associated with the players are enclosed in the Nocturnal Polyuria Treatment market report. Future Market Insights, in its latest business report, elaborates on the current situation of the global Nocturnal Polyuria Treatment market in terms of volume, value, production, and consumption. The report scrutinizes the market into various segments, end uses, regions, and players on the basis of demand patterns, and future prospects. Understanding the Impact of Covid-19 on Healthcare Industry With the pandemic plaguing maximum countries across the globe, healthcare industry is witnessing its fair share of ‘ups and downs’. The COVID-19 has placed an enormous strain on the healthcare sector’s workforce, facilities and infrastructure. Despite the endless pressure, healthcare sector is growing at a moderate pace due to the improvement in infrastructure and advancement in technology, healthcare sector is delivering a healthy performance. The FMI’s latest report on the Nocturnal Polyuria Treatment market gives a detailed analysis on the impact of COVID-19 with an incisive coverage on the innovative strategies adopted by the market players to survive the challenges due to pandemic. Request For Table Of Content @ https://www.futuremarketinsights.com/toc/rep-gb-11502 Report Highlights: Any Queries, Contact Us @ https://www.futuremarketinsights.com/askus/rep-gb-11502 Critical Questions Answered in the Report What are ongoing trends that will shape market growth curve for global Nocturnal Polyuria Treatment market? What are the drivers and challenges affecting the Nocturnal Polyuria Treatment market demand? What are the recent technological advancement in the Nocturnal Polyuria Treatment market? What are key trends and opportunities that will prevail the revenue growth of Nocturnal Polyuria Treatment market players? How will evolving regulatory policies impact the market growth? What is the impact of Covid-19 on the Nocturnal Polyuria Treatment market? Reasons to Buy the report We provide authentic and detailed an analysis on various market trends to enable businesses to make informed and beneficial decisions to attain competitive edge over key players. Our analysts provide detailed market segmentation along with meaningful insights and extensive reports that other companies fail to include. The report includes accurate analysis of the market and the current developing trends affecting the growth. FMI speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, industry experts. This ensures that the data collected is from highly reliable sources. Why Future Market Insights? Detailed insights of market segments and sub-segments for historical as well as forecast period A competitive analysis of prominent players and emerging players in the Nocturnal Polyuria Treatment market Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario Explore Wide-ranging Coverage of FMI’s Healthcare Market Insights Landscape Home Respiratory Therapy Market – Home Respiratory Therapy Market: Global Industry Analysis 2015 – 2019 and Opportunity Assessment 2020 – 2030 Plasma-derived Protein Therapies Market – Plasma-derived Protein Therapies Market: Global Industry Analysis 2015 – 2019 and Opportunity Assessment 2020 – 2030 Olaparib API Market – Olaparib API Market: Global Industry Analysis 2015 – 2019 and Opportunity Assessment 2020 – 2030 About FMI Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers. Contact
Vantia Therapeutics Frequently Asked Questions (FAQ)
Where is Vantia Therapeutics's headquarters?
Vantia Therapeutics's headquarters is located at Epsilon House Southampton Science Park, Hampshire.
What is Vantia Therapeutics's latest funding round?
Vantia Therapeutics's latest funding round is Series B.
How much did Vantia Therapeutics raise?
Vantia Therapeutics raised a total of $44.13M.
Who are the investors of Vantia Therapeutics?
Investors of Vantia Therapeutics include SV Health Investors, MVM Partners and Novo Ventures.
Who are Vantia Therapeutics's competitors?
Competitors of Vantia Therapeutics include Endocare, Intercept Pharmaceuticals, Eiger BioPharmaceuticals, AnaptysBio, Tolera Therapeutics and 12 more.
Compare Vantia Therapeutics to Competitors
Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.
Slate currently markets Testopel in the United States. Testopel is an FDA-approved subcutaneous implantable testosterone pellet. Testopel is used for the treatment of testosterone deficiency in aging men as well as androgen deficiency caused by other conditions.
Lumavita AG is a biopharmaceutical company focusing on novel anti-infectives for women's health. The Company's product portfolio includes FemiFect (pentamycin) a polyene macrolide with a unique spectrum of coverage for the treatment of vaginitis, and LMV-601, a first-in-class PC- PLC inhibitor for the potential treatment of infection of the cervix caused by Human Papilloma Virus. A dose-optimized formulation of FemiFect is in Ph IIb clinical development, and LMV-601 is in late-stage pre-clinical development. Lumavita AG is headquartered in Basle, Switzerland.
Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.
CMP Therapeutics has developed a treatment for regulating and stimulating the immune system. The lead product is in Phase II clinical trials for allergic disorders. Other pipeline products have shown through stimulation of the immune system to protect against viruses and bacteria.
Imvision2ImVisioN Therapeutics AG (Muttenz, Switzerland) is engaged in intralymphatic immunotherapy (ILIT), a technology for the delivery of immunotherapeutics in the treatment of allergies. ImVisioN's lead product for the treatment of cat dander allergy is in clinical development.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.